International Paper Indefinite-Lived Research and Development Assets decreased by 97.9% to $5.00M in Q4 2025 compared to the prior quarter. Over 2 years (FY 2023 to FY 2025), Indefinite-Lived Research and Development Assets shows a downward trend with a -82.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
indefinite_lived_rd_assets| Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|
| Value | $162.00M | $240.00M | $5.00M |
| QoQ Change | — | +48.1% | -97.9% |
| YoY Change | — | +48.1% | -97.9% |